about
Emerging drugs for cervical cancer.MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids.Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathwaysRepotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Diana Cervantes-Madrid
@ast
Diana Cervantes-Madrid
@en
Diana Cervantes-Madrid
@es
Diana Cervantes-Madrid
@nl
type
label
Diana Cervantes-Madrid
@ast
Diana Cervantes-Madrid
@en
Diana Cervantes-Madrid
@es
Diana Cervantes-Madrid
@nl
prefLabel
Diana Cervantes-Madrid
@ast
Diana Cervantes-Madrid
@en
Diana Cervantes-Madrid
@es
Diana Cervantes-Madrid
@nl
P106
P21
P31
P496
0000-0003-1071-1407